MedinGlobal

Edit Template

BDRON 500MG

In Stock

BDRON 500MG contains Abiraterone acetate 500MG and is listed as a prescription anticancer medicine associated with the treatment of metastatic prostate cancer in selected patients. It belongs to the androgen synthesis inhibitor class and works by blocking CYP17-mediated androgen production, reducing hormones that can drive certain prostate cancers. Treatment requires specialist supervision, appropriate clinical assessment and regular monitoring.

Medinglobal provides medicine information and enquiry coordination. It does not manufacture, sell or dispense medicines directly. Availability and any subsequent supply are subject to verification by an appropriately authorised independent provider and applicable regulations.

BDRON 500MG – Composition, Uses and Medicine Enquiries

Product Overview

BDRON 500MG is listed as a prescription product containing Abiraterone acetate 500MG, marketed in the source catalogue by Bdr Pharmaceuticals Internationals Pvt Ltd.

It belongs to the androgen synthesis inhibitor; oncology class and may be prescribed for metastatic prostate cancer in selected patients. Its active ingredient blocks CYP17-mediated androgen production, reducing hormones that drive some prostate cancers.

The suitability of treatment depends on the confirmed diagnosis, previous treatment, organ function, other medicines and the treating specialist’s assessment.

The exact manufacturer pack, formulation, approved indication and administration schedule must be checked before treatment or publication. A qualified clinician should assess suitability, interactions, contraindications and monitoring requirements.

Composition and Strength

The supplied product information identifies the following composition:

Active Ingredient Strength
Abiraterone acetate 500MG

Product Name: BDRON 500MG

Generic Name: Abiraterone acetate

Brand Name: BDRON 500MG

Strength: 500MG

Listed Marketer: Bdr Pharmaceuticals Internationals Pvt Ltd

The composition and strength should be verified against the original manufacturer-labelled packaging before publication or any medicine enquiry.

Therapeutic Category and Indication

BDRON 500MG belongs to the anticancer category and is classified as an androgen synthesis inhibitor within oncology.

It may be prescribed for metastatic prostate cancer in selected patients.

Abiraterone acetate blocks CYP17-mediated androgen production, reducing hormones that can support the growth of certain prostate cancers.

Treatment choice depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.

Blood pressure, potassium levels, liver tests and pregnancy-handling precautions require specialist review.

Administration Information

The supplied product information identifies oral tablets taken fasting according to the product label.

Treatment is generally given with a prescribed corticosteroid and androgen-deprivation treatment.

Patients should follow only the treating clinician’s instructions and the approved product label. They should not independently adjust the dose, skip safety monitoring or switch formulations without medical advice.

The exact administration schedule must be verified against the approved product information.

Product Presentation and Availability

The product enquiry can be made using the following details:

  • Product Name: BDRON 500MG
  • Generic Name: Abiraterone acetate
  • Strength: 500MG
  • Company Name: Bdr Pharmaceuticals Internationals Pvt Ltd
  • Therapeutic Category: Anticancer
  • Medicine Class: Androgen Synthesis Inhibitor; Oncology
  • Indication: Metastatic prostate cancer in selected patients
  • Administration: Oral tablets

The exact dosage form, pack size, batch, storage, expiry and product-specific presentation require verification from original manufacturer packaging and an authorised provider.

Product details and supply eligibility may vary by country. A product listing does not confirm current stock or availability.

Prescription and Patient Safety

BDRON 500MG is listed as a prescription medicine and requires assessment by a qualified healthcare professional.

Treatment suitability, contraindications, interactions and monitoring requirements must be evaluated by the treating specialist.

Blood pressure, potassium levels and liver tests require specialist review. Pregnancy-handling precautions should also be assessed.

Patients should follow the approved product label and their clinician’s instructions. This product information does not replace individual medical advice.

Medicine Enquiry Coordination Through Medinglobal

Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.

Medinglobal does not itself sell, dispense, manufacture or export medicines.

Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.

How to Submit a BDRON 500MG Enquiry

To help identify the requested product, include the following details:

  1. Product name: BDRON 500MG.
  2. Generic name: Abiraterone acetate.
  3. Required strength: 500MG.
  4. Required formulation and quantity.
  5. Destination country.
  6. Valid prescription or institutional documents, where required.

Medinglobal may coordinate an introduction to a suitably authorised provider. The provider independently verifies product details, regulatory eligibility and any transaction.

Frequently Asked Questions

What is BDRON 500MG used for?

BDRON 500MG is associated with metastatic prostate cancer in selected patients. The treating prescriber confirms the approved use and suitability.

What is the composition of BDRON 500MG?

The supplied catalogue lists Abiraterone acetate 500MG as its active ingredient. The composition should be verified against the original product packaging.

How is BDRON 500MG administered?

The supplied information identifies oral tablets taken fasting according to the product label, generally with prescribed corticosteroid and androgen-deprivation treatment.

Which company is listed for BDRON 500MG?

Bdr Pharmaceuticals Internationals Pvt Ltd is listed as the marketer in the supplied product information.

Does BDRON 500MG require medical supervision?

Yes. Treatment suitability, interactions, contraindications and monitoring requirements must be assessed by a qualified specialist.

Can Medinglobal supply BDRON 500MG directly?

No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.

Product Name

Generic Name

Brand Name

Composition

Strength

Therapeutic Category

Medicine Class

Indication

Dosage Form

Route of Administration

Reviews

There are no reviews yet.

Be the first to review “BDRON 500MG”

Your email address will not be published. Required fields are marked *

Pharmaceutical Disclaimer

Medinglobal Platform does not sell, dispense, manufacture or prescribe medicines. Pharmaceutical information on this page is provided solely for general information, product identification and enquiry coordination. Product listing is not medical advice, a recommendation or an offer for sale by Teji Radiance or the Medinglobal Partnership Firm. Prescription medicines require a valid prescription where applicable. Any regulated pharmaceutical activity is undertaken by the relevant independent provider subject to applicable law. Always consult an appropriately qualified healthcare professional before using or changing any medicine.

Scroll to Top